Frost F, Young GR, Wright L, et al. - By performing this open-label randomised crossover pilot trial at a UK cystic fibrosis (CF) centre, researchers assessed the clinical as well as microbiological results related to substituting inhaled aztreonam lysine for an intravenous antibiotic in the management of acute pulmonary exacerbations of CF. Participants included 16 adults suffering from CF and P. aeruginosa infection. Over the course of two exacerbations, patients were randomly assigned to sequentially receive 14 days of inhaled aztreonam lysine plus IV colistimethate (AZLI+IV), or dual IV antibiotics (IV+IV). According to findings, improved lung function and quality of life were conferred by AZLI+IV vs the current standard treatment in adults with CF and P. aeruginosa infection encountering an acute pulmonary exacerbation. The requirement for larger definitive trials of inhaled antibiotics in the acute setting is supported by these data.